Canadian Corporate News - Biovail Acquires Ativan and Isordil from Wyeth.
TORONTO, ONTARIO, Jun 2, 2003 (CCNMatthews via COMTEX)
— Anxiety treatment Ativan complements Biovail’s growing CNS franchise
— Isordil further expands Biovail’s cardiovascular product line
Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has acquired U.S. rights to the Ativan(R) (lorazepam) and Isordil(R) (isosorbide dinitrate) oral product lines from Wyeth (NYSE:WYE) for $130 million and annual payments pursuant to a three year supply agreement. Sales of Ativan and Isordil in the U.S. were in excess of $50 million in 2002.
Related Results
Biovail Acquires Ativan and Isordil from Wyeth.
Disease management: behavioral healthcare’s road to carve-in status: will thi…
Lost in the shuffle
New Medicare facts could bring real fear this fall
Exchange
Ativan is a benzodiazepine, …
Read the rest of this article with a Free Trial at HighBeam Research.
